

Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent hemodialysis

Fritz Sörgel^{1,2*}, Jakob J. Malin^{3-5*}, Henning Hagmann^{4,6}, Martina Kinzig¹, Muhammad Bilal⁷, Dennis A. Eichenauer⁸, Oliver Scherf-Clavel^{1,9}, Alexander Simonis^{3,4}, Lobna El Tabei⁷, Uwe Fuhr^{7#}, Jan Rybniker^{3-5#}

1 IBMP – Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Straße 19, D-90562 Nürnberg-Heroldsberg, Germany

2 Institute of Pharmacology, West German Heart and Vascular Centre, University of Duisburg-Essen, Essen, Germany

3 Department I of Internal Medicine, Division of Infectious Diseases, University of Cologne, Cologne, Germany

4 Faculty of Medicine, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany

5 German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany

6 Department II of Internal Medicine, University Hospital Cologne, Cologne, Germany

7 Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, University of Cologne, Cologne, Germany

8 University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, Intensive Care Program, Cologne, Germany.

9 University of Wuerzburg, Institute for Pharmacy and Food Chemistry, Wuerzburg, Germany

* authors contributed equally

corresponding authors:

Jan Rybniker, M.D., Ph.D.; ID-specialist
Faculty of Medicine and University Hospital Cologne
Department I of Internal Medicine; Division of Infectious Diseases
University of Cologne, Cologne, Germany
Email: jan.rybniker@uk-koeln.de

Uwe Fuhr, M.D.; Professor of Pharmacology
Faculty of Medicine and University Hospital Cologne
Center for Pharmacology
Acting Director, Department I of Pharmacology
University of Cologne, Cologne, Germany
Email: uwe.fuhr@uk-koeln.de

1 **Abstract**

2 Remdesivir, a drug with provisional approval for the treatment of COVID-19, is not recommended in
3 patients with an estimated glomerular filtration rate ≤ 30 mL/min. Here we provide a first detailed
4 pharmacokinetic assessment of remdesivir and its major metabolites in a patient with end stage
5 renal disease on hemodialysis.

6 **Introduction**

7 Remdesivir has been authorized for emergency use in patients with severe SARS-CoV-2 infection [1]
8 as it reduced the median time to recovery from COVID-19 in a randomized controlled trial [2]. Due to
9 a lack of data, remdesivir is not recommended for patients with an estimated glomerular filtration
10 rate (eGFR) ≤ 30 mL/min, including those with end-stage renal disease (ESRD), which represents a
11 substantial limitation for COVID-19 treatment in this vulnerable population. Patients with ESRD have
12 an increased risk for a severe course of COVID-19 [3]. Moreover, COVID-19 itself leads to AKI and AKI-
13 associated mortality in a significant proportion of critically ill patients [4]. Thus, it is of high
14 importance to assess safety and pharmacokinetics of remdesivir in patients with renal impairment
15 and those on renal replacement therapy [5].

16 Intracellular remdesivir prodrug (GS-5734) is rapidly converted to its alanine metabolite GS-704277
17 and subsequently to the monophosphate that is finally converted to the active triphosphate GS-
18 443902 [6]. Alternatively, dephosphorylation of the monophosphate yields the remdesivir nucleoside
19 core (GS-441524) which becomes the predominant circulating metabolite providing a potential
20 source of active drug by a slow re-phosphorylation process [7]. In healthy volunteers, renal excretion
21 of a remdesivir dose is about 10% as unchanged drug [8] and about 50 % as GS-441524 [9].

22 Here we report on pharmacokinetics of remdesivir and its metabolites and treatment outcome in a
23 patient on renal replacement therapy without residual renal function suffering from severe COVID-
24 19.

25

26 **Methods**

27 **Administration of remdesivir**

28 Remdesivir was administered as controlled intravenous infusion (500 mL/h) over 30 minutes via
29 femoral vein catheter without any parallel infusions (for doses and timing see figure 1). Markers for
30 hepatotoxicity were monitored at least daily during treatment with remdesivir and for subsequent
31 days (supplementary figure 2).

32 **Pharmacokinetic sampling**

33 Blood samples were drawn from the arterial line after discarding dead space volume. In addition,
34 several blood samples were taken from the inlet and the outlet of the dialysis device to analyze drug
35 elimination during hemodialysis. Polypropylene tubes containing 1.2 mg/mL
36 ethylenediaminetetraacetic acid (EDTA) to prevent clotting and 1 mg/mL of sodium fluoride
37 (Sarstedt, Nümbrecht, Germany) were used and directly placed on ice to prevent *in vitro* hydrolysis of
38 remdesivir [10] and its metabolites before further processing within a maximum of one hour. Plasma
39 was separated by centrifugation at 4°C and subsequently stored at -80°C prior to pharmacokinetic
40 analyses.

41 **Hemodialysis**

42 Hemodialysis was performed using the Fresenius GENIUS® device, a single pass close tank
43 hemodialysis system, containing 90 liters of dialysis fluid. The system was equipped with an FX600
44 CorDiax® hemodialysis filter (Fresenius) and standard blood lines and tubing. The extracorporeal
45 circuit was established via central venous catheter. Blood flow ranged between 150 and 280 mL/min.
46 According to technical design, dialysate flow equaled blood flow. Ultrafiltration settings ranged
47 between 100 and 200 ml/h. Hemodialysis was performed prior to administration of the daily
48 remdesivir dose on days 2 and 5 of treatment. In the two dialysis sessions a blood volume of 88 and
49 90 liters was processed. Duration of treatment was 425 minutes and 315 minutes. Ultrafiltration
50 volume was 990 ml and 1037 ml, respectively. For anticoagulation unfractionated heparin was

51 administered as intravenous bolus of 2000 IE at the beginning of hemodialysis and a rate of 1000 IE/h
52 during treatment.

53 **Determination of remdesivir and metabolites**

54 Measurements of drug concentrations were performed at the Institute for Biomedical and
55 Pharmaceutical Research, Nürnberg-Heroldsberg, Germany. Remdesivir and its metabolite GS-
56 441524 were purchased from BIOSYNTH® Carbosynth (Berkshire, UK). Calibration standards and
57 spiked quality control samples were prepared in drug-free human EDTA plasma. Liquid
58 chromatography/mass spectrometry to detect the compounds used transitions REM 603.3→402.0
59 and 292.2→163.1 (GS-441524) on a SCIEX API 6500TM triple quadrupole mass spectrometer
60 equipped with turbo ion spray interface (SCIEX, Concord, Ontario, Canada). Calibration for both
61 compounds was performed by weighted ($1/\text{concentration}^2$) linear regression. Linearity for remdesivir
62 and GS-441524 in human plasma could be demonstrated over a calibration range from 3.600 to
63 787.4 ng/mL for remdesivir and from 10.84 to 474.5 ng/mL for GS-441524. Quantification of
64 remdesivir and GS-441524 was performed by peak area ratio of analyte to internal standard
65 (remdesivir: piperacillin-d5, GS-441524 amoxicillin-d4). When samples were outside that range a
66 dilution by drug free human plasma was used. No interferences were observed for remdesivir and
67 GS-441524 and the internal standards in human plasma. Since there was no reference standard
68 available for the intermediate metabolite GS-704277, only the time course of plasma concentrations
69 could be described which were obtained from peak heights relative to an internal standard
70 (transition 443.1→202.1).

71 **Pharmacokinetic assessment**

72 Pharmacokinetic parameters following the first dose for remdesivir and its metabolites were
73 calculated by standard non-compartmental methods. Extraction of GS-441524 by dialysis was
74 calculated as

75 (1-outlet concentration [corrected for volume loss] / inlet concentration). The observed decrease of

76 GS-441524 extraction during dialysis was described by linear regression with cumulative blood flow.

77

78 Results and Discussion


79 In September 2020, a male patient in his seventies was admitted to the Hospital and diagnosed with
80 COVID-19 (Supplementary tables 1 and 2). Initially, he presented with typical pulmonary infiltrates
81 and normal arterial blood gas results. However, clinical status deteriorated rapidly and
82 dexamethasone treatment was initiated. At this time-point, remdesivir was not considered due to
83 chronic renal impairment requiring renal replacement therapy. Sequential CT scans revealed
84 progression of pulmonary infiltrates (Supplementary figure 1). Nine days after initial admission, the
85 patient was transferred to the ICU with hypoxemic lung failure requiring high-flow oxygen therapy. In
86 this critical situation, we decided to apply remdesivir while performing extensive therapeutic drug
87 monitoring of the prodrug and two metabolites for safety reasons. Remdesivir concentrations
88 decreased rapidly after the first infusion with an apparent half-life of 1.1 hours and were below the
89 lower limit of quantification prior to dialysis (fig 1; supplementary tables 3 and 4). GS-441524
90 concentrations increased up to 1 µg/mL and remained essentially constant. Exposure for remdesivir
91 ($AUC_{0-\infty}$ 13.0 µg/mL*h, C_{max} 19.8 µg/mL) and GS-441524 ($AUC_{0-20.1 h}$ 18.4 µg/mL*h, C_{max} 1.15 µg/mL)
92 after the first dose was about 3-fold and 6-fold higher in our patient as compared to healthy
93 volunteers (Supplementary tables 3 and 4) [8] which is in agreement with a preliminary observation
94 in a critically ill patient with reduced renal function [11]. Both remdesivir clearance and volume of
95 distribution were clearly lower in our patient, which may be attributable to his low body weight (53.2
96 kg). Hemodialysis performed prior to the second and the 5th dose of remdesivir reduced GS-441524
97 plasma concentrations by about 50% (fig. 1). The initial extraction rate of dialysis was 72% and
98 decreased to 42% at the end of dialysis (Supplementary table 5). Trough concentrations of GS-
99 441524 were high but stable between dialysis sessions (range 1.66 to 1.79 µg/mL), while remdesivir
100 trough concentrations were always below the lower limit of quantification (fig. 1, supplementary
101 tables 3 and 4). Thus, we did not observe significant accumulation of remdesivir and accumulation of
102 GS-441524 was prevented by intermittent hemodialysis.

103 Accumulation of the vehicle sulfobutylether-beta-cyclodextrin (SBECD) may occur in renal failure [12]
104 and high doses were associated with significant hepatic and renal toxicity in animals [13]. However,
105 reported toxic doses were 50-100 times higher than exposure during a 5-10 day course of remdesivir.
106 In addition, it was shown that SBECD is eliminated by renal replacement therapy [14, 15]. Although
107 we did not measure SBECD concentrations in this study, clinically significant accumulation of SBECD
108 seems unlikely given the limited treatment duration and intermittent hemodialysis.

109 Overall, there were no signs of drug related toxicity. Markers for hepatic injury remained within the
110 reference ranges during treatment and up to 8 days of follow up (Supplementary figure 2). An
111 isolated increase in International Normalized Ratio (INR) was observed, which improved after vitamin
112 K supplementation and therefore was not considered as treatment related (Supplementary figure 2).
113 By day 5 of remdesivir treatment, oxygenation parameters had improved allowing for patient
114 transfer to a hospital ward.

115 Our observation support the safety of remdesivir in patients with ESRD on hemodialysis, which will
116 assist clinical decision making and guide future clinical trial design.

117



118

119 **Figure 1.** Pharmacokinetics of the prodrug remdesivir (GS-5734), its intermediate alanine metabolite
120 (GS-704277) and the predominant circulating metabolite GS-441524 during a standard 5-day regimen
121 in a patient with intermittent hemodialysis due to long lasting ESRD. Arterial blood samples were
122 drawn in conjunction to initial administration of remdesivir and hemodialysis (d1, d4). In addition,
123 GS-441524 concentrations in samples from dialysis outlet (gray triangles) are shown that were taken
124 to assess elimination by hemodialysis.

125

126

127 **References**

- 128 1. European Medicines Agency (EMA). Press release on conditional authorization of Veklury
129 (remdesivir). Available on: [www.ema.europa.eu/documents/press-release/ema-receives-](http://www.ema.europa.eu/documents/press-release/ema-receives-application-conditional-authorisation-first-covid-19-treatment-eu_en.pdf)
130 [application-conditional-authorisation-first-covid-19-treatment-eu_en.pdf](http://www.ema.europa.eu/documents/press-release/ema-receives-application-conditional-authorisation-first-covid-19-treatment-eu_en.pdf) (Accessed 1st
131 October 2020).
- 132 2. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final
133 Report. *N Engl J Med* 2020: NEJMoa2007764. DOI: 10.1056/NEJMoa2007764.
- 134 3. Ng JH, Hirsch JS, Wanchoo R, et al. Outcomes of patients with end-stage kidney disease
135 hospitalized with COVID-19. *Kidney Int* 2020: S0085-2538(20)30945-5. DOI:
136 10.1016/j.kint.2020.07.030.
- 137 4. Chan L, Chaudhary K, Saha A, et al. AKI in Hospitalized Patients with COVID-19. *Journal of the*
138 *American Society of Nephrology* 2020: ASN.2020050615. DOI: 10.1681/ASN.2020050615.
- 139 5. Adamsick ML, Gandhi RG, Bidell MR, et al. Remdesivir in Patients with Acute or Chronic
140 Kidney Disease and COVID-19. *J Am Soc Nephrol* **2020**; 31(7): 1384-6.
- 141 6. Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and
142 Other Viral Diseases. *Clinical Microbiology Reviews* **2020**; 34(1): e00162-20. DOI:
143 10.1016/S2213-2600(20)30079-5.
- 144 7. Eastman RT, Roth JS, Brimacombe KR, et al. Remdesivir: A Review of Its Discovery and
145 Development Leading to Emergency Use Authorization for Treatment of COVID-19. *ACS Cent*
146 *Sci* **2020**; 6(5): 672-83.
- 147 8. Humeniuk R, Mathias A, Cao H, et al. Safety, Tolerability, and Pharmacokinetics of
148 Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects. *Clin Transl Sci* **2020**;
149 13(5): 896-906.
- 150 9. Food and Drug Administration (FDA). FACT SHEET FOR HEALTH CARE PROVIDERS
151 EMERGENCY USE AUTHORIZATION (EUA) OF VEKLURY® (remdesivir). 2020. Available on:
152 www.fda.gov/media/137566/download (accessed: 1st October 2020).
- 153 10. Scherf-Clavel O, Kaczmarek E, Kinzig M, et al. Tissue level profile of SARS-CoV-2 antivirals in
154 mice to predict their effects in COVID-19 multiorgan failure. *bioRxiv* 2020:
155 2020.09.16.299537. DOI: 10.1101/2020.09.16.299537.

- 156 11. Tempestilli M, Caputi P, Avataneo V, et al. Pharmacokinetics of remdesivir and GS-441524 in
157 two critically ill patients who recovered from COVID-19. *J Antimicrob Chemother* **2020**;
158 75(10): 2977-80.
- 159 12. Hoover RK, Alcorn H, Jr., Lawrence L, et al. Clinical Pharmacokinetics of Sulfobutylether- β -
160 Cyclodextrin in Patients With Varying Degrees of Renal Impairment. *J Clin Pharmacol* **2018**;
161 58(6): 814-22.
- 162 13. Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical
163 pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). *J Pharm Sci* **2010**; 99(8): 3291-
164 301.
- 165 14. Luke DR, Wood ND, Tomaszewski KE, Damle B. Pharmacokinetics of sulfobutylether- β -
166 cyclodextrin (SBECD) in subjects on hemodialysis. *Nephrol Dial Transplant* **2012**; 27(3): 1207-
167 12.
- 168 15. Kiser TH, Fish DN, Aquilante CL, et al. Evaluation of sulfobutylether- β -cyclodextrin (SBECD)
169 accumulation and voriconazole pharmacokinetics in critically ill patients undergoing
170 continuous renal replacement therapy. *Crit Care* **2015**; 19(1): 32.
- 171